Ultragenyx Pharmaceu (RARE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 560,230 | 434,249 | 363,329 | 351,406 | 271,030 |
| Cost of Goods | 76,728 | 45,209 | 28,320 | 16,008 | 6,129 |
| Gross Profit | 483,502 | 389,040 | 335,009 | 335,398 | 264,901 |
| Operating Expenses | 1,020,203 | 958,457 | 984,248 | 717,143 | 595,146 |
| Operating Income | -535,973 | -569,208 | -648,919 | -381,737 | -330,116 |
| Interest Expense | 63,041 | 66,004 | 43,015 | 29,422 | 33,291 |
| Other Income | 31,428 | 26,748 | -9,791 | -41,822 | 178,048 |
| Pre-tax Income | -567,586 | -608,464 | -701,725 | -452,981 | -185,359 |
| Income Tax | 1,597 | -1,825 | 5,696 | 1,044 | 1,207 |
| Net Income Continuous | -569,183 | -606,639 | -707,421 | -454,025 | -186,566 |
| Net Income | $-569,183 | $-606,639 | $-707,421 | $-454,025 | $-186,566 |
| EPS Basic Total Ops | -6.29 | -8.25 | -10.12 | -6.70 | -3.07 |
| EPS Basic Continuous Ops | -6.29 | -8.25 | -10.12 | -6.70 | -3.07 |
| EPS Diluted Total Ops | -6.29 | -8.25 | -10.12 | -6.70 | -3.07 |
| EPS Diluted Continuous Ops | -6.29 | -8.25 | -10.12 | -6.70 | -3.07 |
| EPS Diluted Before Non-Recurring Items | -6.29 | -8.25 | -9.05 | -6.34 | -5.28 |
| EBITDA(a) | $-513,054 | $-556,044 | $-628,000 | $-361,892 | $-317,007 |